首页> 外文OA文献 >Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States

【2h】

Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States

机译：omalizumab的成本效果用于治疗美国中度至严重的不受控制的过敏性哮喘

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Patrick W. Sullivan; Qianyi Li; S. Pinar Bilir; Joseph Dang; Abhishek Kavati; Ming Yang; Yamina Rajput;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States [J] . Sullivan Patrick W., Li Qianyi, Bilir S. Pinar, Current medical research and opinion . 2020,第1期

机译：omalizumab的成本效果用于治疗美国中度至严重的不受控制过敏性哮喘
2. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. [J] . Oba Y, Salzman GA The Journal of Allergy and Clinical Immunology . 2004,第2期

机译：omalizumab在中度至重度过敏性哮喘的成人和青少年中的成本效果分析。
3. Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US [J] . Zafar Zafari, Mohsen Sadatsafavi, J. Mark FitzGerald Cost Effectiveness Resource Allocation . 2018,第1期

机译：Tiotropium对Omalizumab对我们来说不受控制过敏性哮喘的成本效益
4. Connections of Reduced Performance Health Data for Severe Persistent Uncontrolled Allergic Asthma Treated by Omazulimab [C] . Stefanos Matsopoulos, Valentina Plekhanova International Conference on Health Informatics . 2014

机译：omazulimab治疗严重持续不受控制的过敏性过敏性哮喘的性能健康数据减少的连接
5. The effect of omalizumab on free IgE and spirometric measurements in allergic asthmatics with highly elevated IgE levels. [D] . Bonilla, Sheila M. 2011

机译：奥马珠单抗对IgE水平升高的过敏性哮喘患者中游离IgE和肺活量测定的影响。
6. Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma [O] . Zafar Zafari, Mohsen Sadatsafavi, Carlo A. Marra, 2011

机译：支气管热成形术，奥马珠单抗和中度至重度过敏性哮喘的标准疗法的成本效益
7. PBI12 COST-EFFECTIVENESS ANALYSIS OF OMALIZUMAB IN THE TREATMENT OF UNCONTROLLED SEVERE ALLERGIC ASTHMA IN CHINA [O] . S. Zhu, D. Xiao, L. Wang, 2019

机译：omalizumab在中国不受控制严重过敏性哮喘治疗中的PBI12成本效益分析

Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States

著录项

引文网络

相似文献

相关主题

期刊订阅